title: Bevacizumab for recurrent primary central nervous system lymphoma: a new treatment?
authors.affiliation: Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois (K.N., J.R.); Department of Medicine (Hematology/Oncology), Northwestern University, Feinberg School of Medicine, Chicago, Illinois (L.I.G., J.R.); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois (L.I.G., J.R.).
authors.forename: Karina
authors.initials: K
authors.lastname: Nieto
authors.affiliation: Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois (K.N., J.R.); Department of Medicine (Hematology/Oncology), Northwestern University, Feinberg School of Medicine, Chicago, Illinois (L.I.G., J.R.); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois (L.I.G., J.R.).
authors.forename: Leo I
authors.initials: LI
authors.lastname: Gordon
authors.affiliation: Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois (K.N., J.R.); Department of Medicine (Hematology/Oncology), Northwestern University, Feinberg School of Medicine, Chicago, Illinois (L.I.G., J.R.); Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois (L.I.G., J.R.).
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Raizer
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D008727:Methotrexate
keywords: PCNSL; bevacizumab